Sujiet Puthenveetil
Director- Antibody Drug Conjugates & Radioconjugates AstraZeneca
Dr. Sujiet Puthenveetil is a Director of Antibody-Drug Conjugates (ADCs) and Radioconjugates at AstraZeneca, where he leads the development of next-generation cancer therapeutics. With over a decade of specialized experience, his career includes key scientific roles at AbbVie and Pfizer, where he pioneered high-throughput conjugation methodologies and novel payload-linker strategies. He began his industry career advancing bioconjugation techniques and analytics for ADCs. Dr. Puthenveetil completed his postdoctoral training in protein engineering at MIT and holds a Ph.D. in Chemical Biology from the University of Utah. His expertise bridges chemistry and biology to drive innovation in targeted therapeutics.
